Plexus Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Plexus in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Plexus stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLXS, but not buy additional shares or sell existing shares.
View analyst ratings for Plexus or view top-rated stocks.

Wall Street analysts have given Plexus a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Plexus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Plexus is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021.
View our earnings forecast for Plexus.

Plexus Corp. (NASDAQ:PLXS) issued its earnings results on Tuesday, April, 20th. The technology company reported $1.49 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.24. The technology company had revenue of $881 million for the quarter, compared to analyst estimates of $879.88 million. Plexus had a trailing twelve-month return on equity of 15.55% and a net margin of 4.35%. The business's quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.61 earnings per share.
View Plexus' earnings history.

Plexus' stock was trading at $60.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PLXS stock has increased by 48.2% and is now trading at $89.95.
View which stocks have been most impacted by COVID-19.

Plexus updated its third quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of 1.230-1.380 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.210. The company issued revenue guidance of $875 million-$915 million, compared to the consensus revenue estimate of $886.50 million.

5 brokers have issued 12-month price objectives for Plexus' shares. Their forecasts range from $78.00 to $110.00. On average, they anticipate Plexus' stock price to reach $93.40 in the next year. This suggests a possible upside of 3.8% from the stock's current price.
View analysts' price targets for Plexus or view top-rated stocks among Wall Street analysts.

80 employees have rated Plexus CEO Todd Kelsey on Glassdoor.com. Todd Kelsey has an approval rating of 77% among Plexus' employees.

Some companies that are related to Plexus include Trimble (TRMB), IPG Photonics (IPGP), Jabil (JBL), Mercury Systems (MRCY), Fabrinet (FN), Sanmina (SANM), Methode Electronics (MEI), TTM Technologies (TTMI), CTS (CTS), Benchmark Electronics (BHE), Park Aerospace (PKE), Key Tronic (KTCC) and Neonode (NEON).
View all of PLXS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Plexus investors own include Bristol-Myers Squibb (BMY), Pfizer (PFE), Walgreens Boots Alliance (WBA), Berry Global Group (BERY), Cisco Systems (CSCO), Intel (INTC), QUALCOMM (QCOM), Teledyne FLIR (FLIR), First Solar (FSLR) and Gilead Sciences (GILD).

Plexus trades on the NASDAQ under the ticker symbol "PLXS."

Plexus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.65%), Dimensional Fund Advisors LP (6.49%), Disciplined Growth Investors Inc. MN (6.15%), Earnest Partners LLC (5.07%), Victory Capital Management Inc. (3.87%) and Fiduciary Management Inc. WI (2.87%). Company insiders that own Plexus stock include Angelo Michael Ninivaggi Jr, David J Drury, Dean A Foate, Michael V Schrock, Patrick John Jermain, Peter Kelly, Ralf R Boer, Ronnie Darroch, Scott Theune, Stephen P Cortinovis, Steven J Frisch, Todd P Kelsey and Yong Jin Lim.
View institutional ownership trends for Plexus.

PLXS stock was sold by a variety of institutional investors in the last quarter, including Disciplined Growth Investors Inc. MN, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Morgan Stanley, Renaissance Technologies LLC, Northern Trust Corp, Fisher Asset Management LLC, and Man Group plc. Company insiders that have sold Plexus company stock in the last year include Angelo Michael Ninivaggi Jr, Dean A Foate, Michael V Schrock, Patrick John Jermain, Ronnie Darroch, Scott Theune, Steven J Frisch, Todd P Kelsey, and Yong Jin Lim.
View insider buying and selling activity for Plexus or view top insider-selling stocks.

PLXS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Fiduciary Management Inc. WI, Earnest Partners LLC, Massachusetts Financial Services Co. MA, Smith Graham & Co. Investment Advisors LP, Royal Bank of Canada, TD Asset Management Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Plexus or or view top insider-buying stocks.

Shares of PLXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLXS stock can currently be purchased for approximately $89.95.

Plexus has a market capitalization of $2.57 billion and generates $3.39 billion in revenue each year. The technology company earns $117.48 million in net income (profit) each year or $4.08 on an earnings per share basis.

Plexus employs 19,500 workers across the globe.

The official website for Plexus is www.plexus.com.

Plexus is headquartered at One Plexus Way, Neenah WI, 54957.

Plexus' mailing address is One Plexus Way, Neenah WI, 54957. The technology company can be reached via phone at 920-969-6000 or via email at [email protected]